CIK 0001650664
- Non-accelerated filer
- Smaller reporting company
Editas Medicine, Inc.
Sign in to watch- Ticker
- EDIT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464097528
- Phone
- +1 617-401-9000
- Business address
- 11 HURLEY ST., CAMBRIDGE, MA, 02141
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $89,088
- in 5 filings, $89K under 10b5-1 plans
Net −$89,088. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-04-14 | MULLEN JAMES C CEO | Grant or award · Stock Option (right to buy) | +170,989 | 170,989 | ||
| 2022-01-03 | MULLEN JAMES C CEO | Sale | −18,252 | $26.95 | $492K | 75,898 |
| 2021-12-22 | MULLEN JAMES C CEO | Grant or award | +36,477 | 94,150 | ||
| 2021-10-18 | MULLEN JAMES C CEO | Sale | −13,805 | $38.03 | $525K | 57,673 |
| 2021-09-30 | MULLEN JAMES C CEO | Grant or award | +36,478 | 71,478 | ||
| 2021-06-14 | MULLEN JAMES C CEO | Grant or award · Stock Option (right to buy) | +170,989 | 170,989 | ||
| 2021-03-02 | MULLEN JAMES C CEO | Purchase | +25,000 | $46.27 | $1.2M | 35,000 |
| 2021-03-02 | MULLEN JAMES C CEO | Grant or award · Stock Option (right to buy) | +196,637 | 196,637 | ||
| 2020-06-10 | MULLEN JAMES C Director | Grant or award · Stock Option (right to buy) | +11,538 | 11,538 | ||
| 2019-06-12 | MULLEN JAMES C Director | Grant or award · Stock Option (right to buy) | +11,538 | 11,538 | ||
| 2018-05-18 | MULLEN JAMES C Director | Purchase | +10,000 | $38.03 | $380K | 10,000 |
| 2018-03-27 | MULLEN JAMES C Director | Grant or award · Stock Option (right to buy) | +23,076 | 23,076 |
Page 1 of 1 · 12 trades